

Sheet 1 of 1

FORM PTO-14 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO.: <b>OC01626K</b>	APPLICATION NO.: <b>10/666,424</b>
	APPLICANT: <b>Kamil Paruch et al.</b>	
	FILING DATE: <b>9/19/2003</b>	GROUP:

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL EP 0 778 277	06/11/1997	EPO			
	AM WO 02/06286	01/24/2002	PCT			
	AN WO 88/04298	06/16/1988	PCT			
	AO					
	AP					

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AQ	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-785.
	AR	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
	AS	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243: 527-536.
	AT	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.
	AU	Shiota et al., "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- $\alpha$ ]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.
	AV	Xasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- $\alpha$ ]pyrimidines", <i>Chem. Pharm. Bull.</i> (1962), 10: 620-626.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 2

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE	
AA								
AB								
AC								
AD								
AE								
AF								
AG								
AH								
AI								
AJ								
AK								

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
AL		WO 2002 060492 A	08/08/2002	WIPO				
AM								
AN								
AO								
AP								

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
AQ								
AR								
AS								
AT								
AU								
AV								

*EXAMINER INITIAL		DATE CONSIDERED
		3/7/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>OC01626K</b>	APPLICATION NO.: <b>10/666,424</b>						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT: <b>Kamil Paruch et al.</b>							
		FILING DATE: <b>09/19/2003</b>		GROUP:					
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE		
	AW								
	AX								
	AY								
	AZ								
	BA								
	BB								
	BC								
	BD								
	BE								
	BF								
	BG								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO		
	BH	WO 02/10162	02/07/2002	WIPO					
	BI								
	BJ								
	BK								
	BL								
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
	BM	A. Sanderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>J. Clin. Oncology</i> , <b>16</b> : 2986-2990 (1998).							
	BN	J. Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem.</i> , <b>224</b> : 771-786 (1994).							
	BO	I. Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5", <i>Eur. J. Biochem.</i> , <b>243</b> : 527-536 (1997).							
	BP	K. S. Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>J. Medicinal Chemistry</i> , <b>45</b> : 3905-3927 (2002).							
	BQ								
	BR								
EXAMINER					DATE CONSIDERED			3/7/06	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									